Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ADS DiagnosticsBOM:523031 EBITDA Margin % is 7.63% as of Mar. 2026, which is 31% below its 10-year median of 11.09. The stock has 3 warning signs investors should review.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. ADS Diagnostics's EBITDA for the
three
months ended in Mar. 2026 was ₹3.1 Mil. ADS Diagnostics's Revenue for the
three
months ended in Mar. 2026 was ₹40.0 Mil. Therefore, ADS Diagnostics's EBITDA margin for the quarter that ended in Mar. 2026 was 7.63%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
ADS Diagnostics EBITDA Margin % Related Terms
ADS Diagnostics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for ADS Diagnostics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BOM:523031 vs OZSC, WHSI, LENSF: EBITDA Margin % Comparison
For the Medical Devices subindustry, ADS Diagnostics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ADS Diagnostics EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, ADS Diagnostics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where ADS Diagnostics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ADS Diagnostics (BOM:523031) has a EBITDA Margin % of 7.63% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ADS Diagnostics and its competitors. This is 31% below median its historical median of 11.09.
Is ADS Diagnostics' EBITDA Margin % too high?
ADS Diagnostics' current EBITDA Margin % of 7.63% is 31% below median its 10-year median of 11.09. The Medical Devices & Instruments industry median EBITDA Margin % is 7.52. ADS Diagnostics' value of 7.63% is 1.5% above this industry median.
How does ADS Diagnostics' EBITDA Margin % compare to OZSC and WHSI?
ADS Diagnostics' EBITDA Margin % of 7.63% can be compared against companies in the Medical Devices & Instruments industry. The industry median EBITDA Margin % is 7.52. ADS Diagnostics' value of 7.63% is 1.5% above this benchmark. While the company's 10-year median is 11.09 vs. the industry median of 7.52, ADS Diagnostics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ADS Diagnostics's current EBITDA Margin % of 7.63% is 1.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on ADS Diagnostics and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ADS Diagnostics's current EBITDA Margin % is 7.63%, which is 31% below median its own 10-year median of 11.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ADS Diagnostics stock overvalued right now?
ADS Diagnostics (BOM:523031) has a current EBITDA Margin % of 7.63%. The stock's GF Value™ is ₹11.48, compared to a current price of ₹11.34 — trading 1.2% below its estimated fair value. The current EBITDA Margin % is 7.63%, which is 31% below median its 10-year median of 11.09 and 1.5% above the Medical Devices & Instruments industry median of 7.52. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For ADS Diagnostics (BOM:523031), the current EBITDA Margin % is 7.63% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ADS Diagnostics Ltd is an India-based company engaged in the sale of medical equipment. It is focused on the business activity of the sale of trading goods, servicing and installation of medical equipment, lease rental, and distribution. The company generates key revenue from the sale of trading goods. It sells its products and services in India and internationally.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:523031 has been successfully added to your 
